TRAIL pathway targeting therapeutics

References

• Hengartner MO. The biochemistry of apoptosis. Nature. 2000;12(407):770–776.
   Google Scholar
• Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Biol. 2008;9(1).
   PubMed Web of Science ®Google Scholar
• Cain K, Bratton SB, Langlais C, et al. Apaf-1 oligomerizes into biologically active 700-kDa and inactive 1.4-MDa apoptosome complexes. J Biol Chem. 2000;275(9):6067–6070.
   PubMed Web of Science ®Google Scholar
• Bratton SB, Walker G, Srinivasula SM, et al. Recruitment, activation and retention of caspases-9 and −3 by Apaf-1 apoptosome and associated XIAP complexes. Embo J. 2001;20(5):998–1009.
   PubMed Web of Science ®Google Scholar
• Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271(22):12687–12690.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley LK, Smolak LPJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3(6):673–682.
   PubMed Web of Science ®Google Scholar
• Walczak H, Miler RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5(2):157–163.
   PubMed Web of Science ®Google Scholar
• Pan G, O’Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276(5309):111–113.
   PubMed Web of Science ®Google Scholar
• Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277(5327):818–821.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104(2):155–162.
   PubMed Web of Science ®Google Scholar
• Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF- B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 1997;7(6):813–820.
   PubMed Web of Science ®Google Scholar
• Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med. 1997;186(7):1165–1170.
   PubMed Web of Science ®Google Scholar
• Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273(23):14363–14367.
   PubMed Web of Science ®Google Scholar
• Merino D, Lalaoui N, Morizot A, et al. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006;26(19):7046–7055.
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous fadd and caspase-8 to death receptors 4 and 5. Immunity. 2000;12(6):611–620.
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Lawrence DA, Tinel A, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem. 2001;276(49):46639–46646.
   PubMed Web of Science ®Google Scholar
• Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis. 2002;7(4):313–319.
   PubMed Web of Science ®Google Scholar
• Ozoren N, El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia. 2002;4(6):551–557.
   PubMed Web of Science ®Google Scholar
• Wei MC, Korsmeyer SJ. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000;14:2060–2071.
   PubMed Web of Science ®Google Scholar
• Luo X, Budihardjo I, Zou H, et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94(4):481–490.
   PubMed Web of Science ®Google Scholar
• Wallin RP, Screpanti V, Michaelsson J, et al. Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur J Immunol. 2003;33(10):2727–2735.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Cretney E, Takeda K, et al. Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) contributes to interferon-dependent natural killer cell protection from tumor metastasis. J Exp Med. 2001;193(6):661–670.
   PubMed Web of Science ®Google Scholar
• Takeda K, Smyth MJ, Cretney E, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol. 2001;214(2):194–200.
   PubMed Web of Science ®Google Scholar
• Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis inducing ligand in immune surveillance against tumor development. J Exp Med. 2002;195(2):161–169.
   PubMed Web of Science ®Google Scholar
• Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in tnf-related apoptosis-inducing ligand-deficient mice. J Immunol. 2002;168(3):1356–1361.
   PubMed Web of Science ®Google Scholar
• Schneider P, Thome M, Burns K, et al. TRAIL Receptors 1 (DR4) and 2 (DR5) Signal FADD-dependent apoptosis and activate NF- B. Immunity. 1997;7:831–836.
   PubMed Web of Science ®Google Scholar
• Berg D, Stuhmer T, Siegmund D, et al. Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways. Febs J. 2009;276(23):6912–6927.
   PubMed Web of Science ®Google Scholar
• Jin Z, El-Deiry WS. Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol. 2006;26(21):8136–8148.
   PubMed Web of Science ®Google Scholar
• Ehrhardt H, Fulda S, Schmid I, et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB. Oncogene. 2003;22(25):3842–3852.
   PubMed Web of Science ®Google Scholar
• Henry CM, Martin SJ. Caspase-8 Acts in a non-enzymatic role as a scaffold for assembly of a pro-inflammatory “FADDosome” complex upon TRAIL stimulation. Mol Cell. 2017;65(4): 715–729 e5.
   PubMed Web of Science ®Google Scholar
• Hartwig T, Montinaro A, von Karstedt S, et al. The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. Mol Cell. 2017;65(4):730–742 e5.
   PubMed Web of Science ®Google Scholar
• Lin Y, Devin A, Cook A, et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of I B kinase and c-Jun N-terminal kinase. Mol Cell Biol. 2000;20(18):6638–6645.
   PubMed Web of Science ®Google Scholar
• Minji J, Kim T-H, Seol D-W, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000;6(5):564-567.
   Web of Science ®Google Scholar
• Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 2001;7(4):383–385.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Eckhardt SG, Kurzrock R, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010;28(17):2839–2846.
   PubMed Web of Science ®Google Scholar
• Soria JC, Mark Z, Zatloukal P, et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(33):4442–4451.
   PubMed Web of Science ®Google Scholar
• Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of apo2l/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther. 2001;299(1):31–38.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Varley KE, Abramson VG, et al. TBCRC 019: a phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer. Clin Cancer Res. 2015;21(12):2722–2729.
   PubMed Web of Science ®Google Scholar
• Ganten TM, Koschny R, Sykora J, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res. 2006;12(8):2640–2646.
   PubMed Web of Science ®Google Scholar
• Berg D, Lehne M, Muller N, et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ. 2007;14(12):2021–2034.
   PubMed Web of Science ®Google Scholar
• Schneider B, Munkel S, Krippner-Heidenreich A, et al. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis. 2010;1(8):e68.
   PubMedGoogle Scholar
• Fang F, Wang AP, Yang SF. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol Sin. 2005;26(11):1373–1381.
   PubMed Web of Science ®Google Scholar
• Geng C, Hou J, Zhao Y, et al. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma. Am J Hematol. 2014;89(11):1037–1042.
   PubMed Web of Science ®Google Scholar
• Chae SY, Kim TH, Park K, et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther. 2010;9(6):1719–1729.
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–151.
   PubMed Web of Science ®Google Scholar
• de Miguel D, Lemke J, Anel A, et al. Onto better TRAILs for cancer treatment. Cell Death Differ. 2016;23(5):733–747.
   PubMed Web of Science ®Google Scholar
• de Bruyn M, Bremer E, Helfrich W. Antibody-based fusion proteins to target death receptors in cancer. Cancer Lett. 2013;332(2):175–183.
   PubMed Web of Science ®Google Scholar
• Allen JE, Krigsfeld G, Patel L, et al. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015;14:99.
   PubMed Web of Science ®Google Scholar
• Allen JE, Krigsfeld G, Mayes PA, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013;5(171):171ra17.
   PubMed Web of Science ®Google Scholar
• Kline CL, Allen JE, Van den Heuvel AP, et al. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2a kinases. Sci Signal. 2015;9:1–10.
   PubMed Web of Science ®Google Scholar
• Ishizawa J, Kojima K, Chachad D, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016;9(415):ra17.
   PubMed Web of Science ®Google Scholar
• Prabhu VV, Allen JE, Dicker DT, et al. Small-molecule onc201/tic10 targets chemotherapy-resistant colorectal cancer stem-like cells in an akt/foxo3a/trail-dependent manner. Cancer Res. 2015;75(7):1423–1432.
   PubMed Web of Science ®Google Scholar
• Prabhu VV, Lulla AR, Madhukar NS, et al. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS One. 2017;12(8):e0180541.
   PubMed Web of Science ®Google Scholar
• Ralff MD, Kline CLB, Kucukkase OC, et al. ONC201 demonstrates anti-tumor effects in both triple negative and non-triple negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms. Mol Cancer Ther. 2017;16(7):1290–1298.
   PubMed Web of Science ®Google Scholar
• Karpel-Massler G, Ba M, Shu C, et al. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Oncotarget. 2015;6(34):36456–36471.
   PubMedGoogle Scholar
• Wagner J, Kline CLB, Zhou L, et al. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest. 2018.
   Web of Science ®Google Scholar
• Stein MN, Bertino JR, Kaufman HL, et al. First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors. Clin Cancer Res. 2017;23(15):4163–4169.
   PubMed Web of Science ®Google Scholar
• Wagner J, Kline CL, Ralff MD, et al. Preclinical evaluation of the imipridone family, analogues of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017;16x.
   PubMed Web of Science ®Google Scholar
• Li B, Russell SJ, Compaan DM, et al. Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. J Mol Biol. 2006;361(3):522–536.
   PubMed Web of Science ®Google Scholar
• Wang G, Wang X, Yu H, et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol. 2013;9(2):84–89.
   PubMed Web of Science ®Google Scholar
• Allen JE, Ferrini R, Dicker DT, et al. Targeting TRAIL death receptor 4 with trivalent DR4 atrimer complexes. Mol Cancer Ther. 2012;11(10):2087–2095.
   PubMed Web of Science ®Google Scholar
• Crowder RN, Dicker DT, El-Deiry WS. The deubiquitinase inhibitor pr-619 sensitizes normal human fibroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cell death. J Biol Chem. 2016;291(11):5960–5970.
   PubMed Web of Science ®Google Scholar
• Mirandola P, Ponti C, Gobbi G, et al. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood. 2004;104(8):2418–2424.
   PubMed Web of Science ®Google Scholar
• Kim K, Fisher MJ, Shi-Qiong X, et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res. 2000;6(2):335–346.
   PubMed Web of Science ®Google Scholar
• Horak P, Pils D, Haller G, et al. Contribution of epigenetic silencing of tumor necrosis factor–related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res. 2005;3(6):335–343.
   PubMed Web of Science ®Google Scholar
• Hopkins-Donaldson S, Ziegler A, Kurtz S, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ. 2003;10(3):356–364.
   PubMed Web of Science ®Google Scholar
• Pai SI, Wu GS, Ozoren N, et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res. 1998;58(16):3513–3518.
   PubMed Web of Science ®Google Scholar
• McDonald ER 3rd, Chui PC, Martelli PF, et al. Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. J Biol Chem. 2001;276(18):14939–14945.
   PubMed Web of Science ®Google Scholar
• Ozoren N, Fischer MJ, Liu CX, et al. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol. 2000;16(5):917–925.
   PubMed Web of Science ®Google Scholar
• Jin Z, McDonald ER 3rd, Dicker DT, et al. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem. 2004;279(34):35829–35839.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res. 2008;6(12):1861–1871.
   PubMed Web of Science ®Google Scholar
• Guan B, Ping Y, Clayman GL, et al. Evidence that the death receptor dr4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol. 2001;188:98–105.
   PubMed Web of Science ®Google Scholar
• Takimoto R, El-Deiry W. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene. 2000;19(14):1735–1743.
   PubMed Web of Science ®Google Scholar
• Earel JK Jr., VanOosten RL, Griffith TS. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 2006;66(1):499–507.
   PubMed Web of Science ®Google Scholar
• Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene. 2005;24(29):4609–4623.
   PubMed Web of Science ®Google Scholar
• Sayers TJ, Murphy WJ. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother. 2006;55(1):76–84.
   PubMed Web of Science ®Google Scholar
• Jiang CC, Chen LH, Gillespie S, et al. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 2007;67(12):5880–5888.
   PubMed Web of Science ®Google Scholar
• Wagner KW, Punnoose EA, Januario T, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med. 2007;13(9):1070–1077.
   PubMed Web of Science ®Google Scholar
• Teitz T, Kidd VJ. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000;6(5):529–535.
   PubMed Web of Science ®Google Scholar
• Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388.
   Web of Science ®Google Scholar
• Krueger A, Schmitz I, Baumann S, et al. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem. 2001;276(23):20633–20640.
   PubMed Web of Science ®Google Scholar
• Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis. 2009;14(4):607–623.
   PubMed Web of Science ®Google Scholar
• Ricci MS, Jin Z, Dews M, et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol. 2004;24(19):8541–8555.
   PubMed Web of Science ®Google Scholar
• Kauh J, Fan S, Xia M, et al. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One. 2010;5(4):e10376.
   PubMed Web of Science ®Google Scholar
• Kim Y, Suh N, Sporn M, et al. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem. 2002;277(25):22320–22329.
   PubMed Web of Science ®Google Scholar
• Clohessy JG, Zhuang J, De Boer J, et al. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem. 2006;281(9):5750–5759.
   PubMed Web of Science ®Google Scholar
• Munshi A, Pappas G, Honda T, et al. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene. 2001;20(29):3757–3765.
   PubMed Web of Science ®Google Scholar
• LeBlanc H, Lawrence D, Varfolomeev E, et al. Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med. 2002;8(3):274–281.
   PubMed Web of Science ®Google Scholar
• Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 2008;68(8):2944–2951.
   PubMed Web of Science ®Google Scholar
• Wang G, Zhan Y, Wang H, et al. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. Cancer Chemother Pharmacol. 2012;69(3):799–805.
   PubMed Web of Science ®Google Scholar
• Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388.
   Web of Science ®Google Scholar
• Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c–dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42.
   PubMed Web of Science ®Google Scholar
• Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102(1):43–45.
   PubMed Web of Science ®Google Scholar
• Fulda S, Wick W, Weller M, et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8(8):808–815.
   PubMed Web of Science ®Google Scholar
• Lin L, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNF-mediated cell death. Science. 2004;305(5689):1471.
   PubMed Web of Science ®Google Scholar
• Choi YE, Butterworth M, Malladi S, et al. The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and −7 via unique mechanisms at distinct steps in their processing. J Biol Chem. 2009;284(19):12772–12782.
   PubMed Web of Science ®Google Scholar
• Yang Y, Fang S, Jensen JP, et al. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science. 2000;288(5467):874–877.
   PubMed Web of Science ®Google Scholar
• Ricci MS, Kim SH, Ogi K, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007;12(1):66–80.
   PubMed Web of Science ®Google Scholar
• Katz SI, Zhou L, Chao G, et al. Sorafenib inhibits ERK1/2 and MCL-1L phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther. 2009;8(24):2406–2416.
   PubMed Web of Science ®Google Scholar
• Abdulghani J, Allen JE, Dicker DT. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One. 2013;8(9):e75414.
   PubMed Web of Science ®Google Scholar
• Zauli G, Sancilio S. PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment. J Cell Physiol. 2005;202(3):900–911.
   PubMed Web of Science ®Google Scholar
• Samuels Y, Diaz LA Jr., Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7(6):561–573.
   PubMed Web of Science ®Google Scholar
• Kandasamy K, Srivastava RK. Role of the Phosphatidylinositol 3 -Kinase/PTEN/Akt Kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res. 2002;62(17):4929–4937.
   PubMed Web of Science ®Google Scholar
• Kim S, Kang J, Qiao J, et al. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J Pediatr Surg. 2004;39(4):516–521.
   PubMed Web of Science ®Google Scholar
• Puduvalli VK, Sampath D, Bruner JM, et al. TRAIL-induced apoptosis in gliomas is enhanced b∗y Akt-inhibition and is independent of JNK activation. Apoptosis. 2005;10:233–243.
   PubMed Web of Science ®Google Scholar
• Panner A, James CD, Berger MS, et al. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol. 2005;25(20):8809–8823.
   PubMed Web of Science ®Google Scholar